Iovance Biotherapeutics Inc
IOVA3.970USD
+0.840+26.84%
Cierre 07/23, 16:00（ET）Cotizaciones retrasadas 15 min
1.33BCap. mercado
PérdidaP/E TTM
Más Datos de Iovance Biotherapeutics Inc Compañía
Iovance Biotherapeutics, Inc. is a commercial biotechnology company. It is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its product, Amtagvi, is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. It is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. It also develops therapies, such as genetically modified TIL cell therapy and cytokines for use in the TIL cell therapy regimen.
Información de la empresa
Símbolo de cotizaciónIOVA
Nombre de la empresaIovance Biotherapeutics Inc
Fecha de salida a bolsaJun 20, 2008
Fundada en2017
Director ejecutivoDr. Frederick G. Vogt, J.D., Ph.D.
Número de empleados838
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 20
Dirección825 Industrial Road
CiudadSAN CARLOS
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal94070
Teléfono16502607120
Sitio Webhttps://www.iovance.com/
Símbolo de cotizaciónIOVA
Fecha de salida a bolsaJun 20, 2008
Fundada en2017
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Frederick G. Vogt, J.D., Ph.D.
Dr. Frederick G. Vogt, J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
404.60K
+8.00%
Dr. Raj K Puri, M.D., Ph.D.
Dr. Raj K Puri, M.D., Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
209.85K
+1.45%
Dr. Michael Weiser, M.D., Ph.D.
Dr. Michael Weiser, M.D., Ph.D.
Independent Director
Independent Director
112.63K
--
Dr. Igor P. Bilinsky, Ph.D.
Dr. Igor P. Bilinsky, Ph.D.
Chief Operating Officer
Chief Operating Officer
93.63K
+6.91%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.00K
--
Mr. Daniel Gordon (Dan) Kirby
Mr. Daniel Gordon (Dan) Kirby
Chief Commercial Officer
Chief Commercial Officer
30.00K
--
Mr. Ryan D. Maynard
Mr. Ryan D. Maynard
Independent Director
Independent Director
7.50K
--
Mr. Matthew W Rosinack
Mr. Matthew W Rosinack
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. Wayne P. Rothbaum
Mr. Wayne P. Rothbaum
Independent Director
Independent Director
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Frederick G. Vogt, J.D., Ph.D.
Dr. Frederick G. Vogt, J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
404.60K
+8.00%
Dr. Raj K Puri, M.D., Ph.D.
Dr. Raj K Puri, M.D., Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
209.85K
+1.45%
Dr. Michael Weiser, M.D., Ph.D.
Dr. Michael Weiser, M.D., Ph.D.
Independent Director
Independent Director
112.63K
--
Dr. Igor P. Bilinsky, Ph.D.
Dr. Igor P. Bilinsky, Ph.D.
Chief Operating Officer
Chief Operating Officer
93.63K
+6.91%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.00K
--
Mr. Daniel Gordon (Dan) Kirby
Mr. Daniel Gordon (Dan) Kirby
Chief Commercial Officer
Chief Commercial Officer
30.00K
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
48.52M
98.37%
Rest of world
804.00K
1.63%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mar., 20 de may
Actualizado: mar., 20 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Quogue Capital L.L.C.
8.40%
The Vanguard Group, Inc.
8.30%
MHR Fund Management LLC
7.31%
BlackRock Institutional Trust Company, N.A.
6.15%
Perceptive Advisors LLC
3.81%
Other
66.02%
Accionistas
Accionistas
Proporción
Quogue Capital L.L.C.
8.40%
The Vanguard Group, Inc.
8.30%
MHR Fund Management LLC
7.31%
BlackRock Institutional Trust Company, N.A.
6.15%
Perceptive Advisors LLC
3.81%
Other
66.02%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
23.17%
Investment Advisor/Hedge Fund
20.36%
Hedge Fund
12.89%
Private Equity
11.13%
Venture Capital
8.50%
Research Firm
4.03%
Bank and Trust
0.57%
Pension Fund
0.57%
Individual Investor
0.37%
Other
18.39%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
643
273.27M
81.83%
-26.86M
2025Q1
680
275.16M
84.08%
-27.55M
2024Q4
654
278.66M
85.07%
-21.74M
2024Q3
641
272.75M
89.13%
-24.76M
2024Q2
630
269.09M
94.68%
-12.01M
2024Q1
622
253.92M
89.61%
-22.91M
2023Q4
605
240.15M
93.91%
-35.32M
2023Q3
601
248.03M
97.72%
-14.72M
2023Q2
594
232.36M
107.55%
-14.37M
2023Q1
607
232.93M
108.05%
+12.27M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Quogue Capital L.L.C.
28.07M
8.4%
--
--
Apr 17, 2025
The Vanguard Group, Inc.
27.73M
8.3%
+243.44K
+0.89%
Mar 31, 2025
MHR Fund Management LLC
24.42M
7.31%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
20.54M
6.15%
+368.21K
+1.83%
Mar 31, 2025
Perceptive Advisors LLC
12.71M
3.81%
-9.40M
-42.51%
Mar 31, 2025
State Street Global Advisors (US)
11.04M
3.31%
-1.21M
-9.86%
Mar 31, 2025
Long Focus Capital Management LLC
9.25M
2.77%
+4.12M
+80.24%
Mar 31, 2025
Hood River Capital Management LLC
9.22M
2.76%
+224.47K
+2.50%
Mar 31, 2025
Soleus Capital Management, L.P.
7.79M
2.33%
+1.23M
+18.67%
Mar 31, 2025
Geode Capital Management, L.L.C.
5.97M
1.79%
+96.88K
+1.65%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: dom., 6 de jul
Actualizado: dom., 6 de jul
Nombre
Proporción
Virtus LifeSci Biotech Products ETF
1.48%
iShares Genomics Immunology and Healthcare ETF
1.06%
WisdomTree BioRevolution Fund
0.53%
SPDR S&P Biotech ETF
0.13%
Direxion Daily S&P Biotech Bull 3X Shares
0.11%
ProShares Ultra Nasdaq Biotechnology
0.07%
Invesco Nasdaq Biotechnology ETF
0.06%
iShares Biotechnology ETF
0.05%
Strive Small-Cap ETF
0.05%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.03%
Ver más
Virtus LifeSci Biotech Products ETF
Proporción1.48%
iShares Genomics Immunology and Healthcare ETF
Proporción1.06%
WisdomTree BioRevolution Fund
Proporción0.53%
SPDR S&P Biotech ETF
Proporción0.13%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.11%
ProShares Ultra Nasdaq Biotechnology
Proporción0.07%
Invesco Nasdaq Biotechnology ETF
Proporción0.06%
iShares Biotechnology ETF
Proporción0.05%
Strive Small-Cap ETF
Proporción0.05%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proporción0.03%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
